ClinicalTrials.gg
CompletedNCT02405858Updated Feb 3, 2025

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

A Phase 4 interventional study of Abiraterone Acetate and Prednisolone in Metastatic Castration-Resistant Prostate Cancer, sponsored by Janssen Pharmaceutical K.K.. Completed at 14 sites in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
53rd of 98
51 · median 56
Started
2015
with 2 others
Phase 4
4 of 98
1 open now
Registered
44th of 98
by date
Lead sponsor
2 of 98
Janssen Pharmaceutical K.K.

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 53rd largest by enrollment, is one of 3 that started in 2015, is one of 4 in phase 4, and was the 44th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2) criteria.

Read the detailed description

This is a Phase 4, non-randomized, multi-center (when more than one hospital work on a medical research study), open label (identity of study drug will be known to participant and study staff), single arm study of abiraterone acetate to investigate its efficacy and safety in participants with metastatic castration-resistant prostate cancer (mCRPC) who failed the first-line combined androgen blockade (CAB) therapy. The study consists of Screening Phase (28 days prior to Cycle 1 Day 1), Treatment Phase (up to 2 years), Post Treatment Phase (30 days after the last dose of study drug). Participants will receive 1000 milligram (mg) (four 250 mg tablets) of abiraterone acetate orally once daily. In addition, 5 mg of oral prednisolone will be concomitantly administered twice a day (10 mg per day). A 28-daily dosing cycle will be continued until disease progression or unacceptable toxicity is observed. The total duration of study will be 2 years. Participants will be primarily evaluated for PSA response. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • Abiraterone Acetate
  • ZYTIGA
  • Prednisolone
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have histologically or cytologically confirm adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
  • Participants who had prostate-specific antigen (PSA) progression defined as a rise of PSA at least 1 week apart resulting in 25 percent (%) increase in PSA with last PSA greater than (>) 2 nanogram per milliliter (ng/mL) (according to PCWG2) after antiandrogen withdrawal
  • Participants who had PSA progression within a year after the start of CAB therapy, or who had PSA progression without having a normal PSA level (less than [\<] 4.0 ng/mL) in the first-line combined androgen blockade (CAB) therapy
  • Participants who have not been treated with cytotoxic chemotherapy (including estramustine) for the treatment of prostate cancer ( or adjuvant chemotherapy is only allowed if the last dose is greater than or equal to [>=] 1 year from the scheduled date of initial administration of abiraterone acetate)
  • Participants who have target or non-target abnormalities either on screening bone scan, computed tomography (CT) or magnetic resonance imaging (MRI)

Exclusion criteria

Exclusion Criteria:

  • A participant who has known allergies, , or intolerance to abiraterone acetate or its
  • A participant who has severe liver dysfunction ( Score C), active or symptomatic viral hepatitis or chronic liver disease
  • A participant who has received other hormonal therapy, including any dose of finasteride, dutasteride, any herbal product known to decrease PSA levels (example: Saw Palmetto and PC-SPES) within 4 weeks prior to the scheduled date of initial administration of abiraterone acetate
  • A participant who has had surgery or local prostatic intervention within 4 weeks prior to the scheduled date of initial administration of abiraterone acetate
  • A participant who has active infection or other medical condition that would make prednisolone use
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Abiraterone Acetate

    Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.

    Drug: Abiraterone Acetate · Drug: Prednisolone

Interventions

  • Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.

    Also known as: ZYTIGA

  • Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Prostate-specific Antigen (PSA) Response (PSA Response Rate) by 12 Weeks of Therapy

    A PSA response is defined as the first occurrence of greater than or equal to (\>=) 50 percent (%) decrease from baseline by 12 weeks after the first dose of study drug, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after the initial documentation.

    Time frame: up to 2 years

Secondary outcomes

  1. Duration of PSA Response

    Duration of PSA response was defined as the duration between the date of confirmed PSA response and subsequent PSA progression date.

    Time frame: Up to 2 years

  2. Time to PSA Response

    Time to PSA response is the time from start of treatment to PSA progression.

    Time frame: Up to 2 years

  3. Percentage of Participants Achieving PSA Response by 24 weeks of Therapy

    A PSA response is defined as the first occurrence of greater than or equal to (\>=) 50 percent (%) decrease from baseline by 24 weeks after the first dose of study drug, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after the initial documentation.

    Time frame: Up to 2 years

  4. PSA-based Progression-free Survival (PSA-PFS)

    PSA-based Progression-free Survival is the time from randomization to the occurrence of one of the following: radiographic progression, clinical progression or death.

    Time frame: Time from randomization up to radiographic progression, clinical progression or death, whichever occurs first (maximum up to 2 years)

  5. Maximum Serum PSA Decline Evaluation

    Maximum PSA Decline will be calculated as Baseline PSA level minus lowest PSA level, observed during the 2 year monthly planned PSA lab test and lowest PSA data will be used for calculating the maximum serum PSA decline.

    Time frame: Baseline and Day 1 of each cycle up to 2 years

  6. Percentage of Participants With Radiographic Objective Response Rate (RAD-ORR) in Participants with Measurable Lesions at Baseline

    Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Baseline, Day 1 of Cycle 1, 2,3 and 4 until first documented disease progression or up to 2 years

  7. Radiographic Progression-free Survival (RAD-PFS)

    RAD-PFS is defined as the time from enrollment to the occurrence of radiographic progression or death.

    Time frame: Time from enrollment up to radiographic progression or death, whichever occurs first (up to 2 years)

  8. Time to Next Treatment

    Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.

    Time frame: up to 2 years

  9. Overall Survival

    Overall survival is defined as the time from enrollment to date of death due to any cause.

    Time frame: Time from enrollment to date of death due to any cause (up to 2 years)

  10. Brief Pain Inventory - Short Form

    Pain will be evaluated using the BPI-SF instrument. Total score is an average of the pain interference score (mean value for the 9 BPI-SF questions \[questions inquiring about the extent of interference with activities by pain, where the extent is ranked from 0 (does not interfere) to 10 (completely interferes)\]) and pain subscale score (mean value for the scores for BPI-SF questions 3, 4, 5 and 6 \[questions inquiring about the extent of pain, where the extent is ranked from 0 (no pain) to 10 (pain as bad as you can imagine)\]). Total score ranges from 0 to 10 with higher values indicating more pain.

    Time frame: Baseline, Day 1 of Cycle 1, 2,3 and 4 up to 2 years

  11. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: up to 2 years

07

Study locations

14 sites
  • Asahi, Japan
  • Higashi-Ibaraki, Japan
  • Kanazawa, Japan
  • Kobe, Japan
  • Koshigaya, Japan
  • Kumamoto, Japan
  • Narashino, Japan
  • Okayama, Japan
  • Sagamihara, Japan
  • Sakura, Japan
  • Shinjuku-Ku, Japan
  • Sunto, Japan
  • Yokohama, Japan
  • Yokosuka, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Dec 2017, 32 months.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2015
First posted
Apr 1, 2015
StartActual
Apr 10, 2015
Primary completionActual
Dec 31, 2017
CompletionActual
Dec 31, 2017
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02405858
Responsible party
Sponsor
First posted
Apr 1, 2015
Start date
Apr 10, 2015
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017
Last update
Feb 3, 2025

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion